Impact of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Randomised Multicentre Study
Year: 2021
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Telemonitoring in type 2 diabetes (T2D) is mainly based on glucose monitoring. A new type of connected device which routinely gathers data on weight, physical activity and food intake could improve patients’ diabetes control. The main aim of this study was to assess the efficacy of an at-home interventional programme incorporating such devices and lifestyle education software on diabetes control, i.e., change in HbA1c, compared to standard care. This multicentre study randomly assigned 282 people with T2D to either a telemonitoring group (TMG) or a control group (CG) for a 1-year intervention period. While routine follow-up was maintained in the CG, TMG subjects were provided with interactive lifestyle educational software (with artificial intelligence algorithms) and connected objects (blood glucose meters, scales and actimeters) for use in their own homes and were remotely monitored by their diabetologists. Changes in HbA 1c were compared between groups using a mixed linear model. The mean HbA 1c dropped from 7.8 ± 0.8% (62 mmol/mol) to 7.4 ± 1.0% (57 mmol/mol) in the TMG and from 7.8 ± 0.8% (62 mmol/mol) to 7.6 ± 1.0% (60 mmol/mol) in the CG, resulting in an intergroup difference of − 0.16 ( p = 0.06) in favour of TMG, after adjustment for confounding factors. Within TMG, the decrease in HbA 1c was greater in frequent users: − 0.23% ( p = 0.03) in the case of connections to telemonitoring synthesis above the median and − 0.21% ( p = 0.05) in the case of connections to tele-education software above the median compared to the CG. Significant weight loss was observed in the TMG but only in women ( p = 0.01). The EDUC@DOM telemonitoring and tele-education device did not highlight a significant decrease in HbA1c levels compared to routine management although a slight, albeit significant improvement in glycaemic control was observed in the frequent user subgroup as well as significant weight loss but only in women. A high level of satisfaction with the connected device was recorded amongst all participants. This trial was registered in the Clinical Trials Database on September 27, 2013, under no. NCT01955031 and bears ID-RCB number 2013-A00391-44.
Source: Diabetes Therapy
Authors: Marie-Christine Turnin, Pierre Gourdy, Jacques Martini, Jean-Christophe Buisson, Marie-Christine Chauchard, Jacqueline Delaunay, Solène Schirr-Bonnans, Soumia Taoui, Marie-France Poncet, Valeria Cosma, Sandrine Lablanche, Magali Coustols-Valat, Lucie Chaillous, Charles Thivolet, Caroline Sanz, Alfred Penfornis, Benoît Lepage, Hélène Colineaux, Michaël Mounié, Nadège Costa, Laurent Molinier, Hélène Hanaire, the Educ@dom Study Group
Institutions: Centre Hospitalier Universitaire de Toulouse, Université Toulouse III - Paul Sabatier, Inserm, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, École Nationale Supérieure d'Électrotechnique, d'Électronique, d'Informatique, d'Hydraulique et des Télécommunications, Clinique Claude-Bernard, Centre Hospitalier Universitaire de Nîmes, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Nantes, Nantes Université, Clinique Pasteur, Université Paris-Saclay, Centre Hospitalier Sud Francilien
Language: English
Subfield: General Health Professions
Field: Health Professions
Domain: Health Sciences
Keywords: type 2 diabetes, remote patient monitoring, artificial intelligence, IoT devices, blood glucose meters, HbA1c, glycemic control, weight loss, user engagement, patient satisfaction, home-based intervention, sex differences, digital health interventions, physical activity monitoring, dietary monitoring
Open Access status: gold
Estimated APC paid: $6,000
Awards: G1191466335, G4188842388, G6628185678
OpenAlex ID: W3174503584
